多西他赛联合奥沙利铂和氟尿嘧啶治疗进展期胃癌的疗效和安全性评价

目的:评价多西他赛?奥沙利铂?氟尿嘧啶联合化疗方案(DOF方案)对进展期胃癌的疗效和不良反应?方法:65例进展期胃癌随机入组DOF方案组(n = 33)和奥沙利铂联合氟尿嘧啶(FOLFOX4)方案组(n = 32),观察两组的临床疗效和不良反应?结果:DOF方案组的有效率(RR)为51.5%,中位无进展时间(TTP)为8.6个月,1年生存率为57.3%;FOLFOX4方案组的RR为46.9%,TTP为5.8个月,1年生存率为41.2%?统计学分析提示,两组客观有效率相似(P > 0.05);DOF方案组的TTP和1年生存率优于FOLFOX4方案组,差异有统计学意义(P < 0.05);DOF方案组的中性粒细胞减少?血小板减少和脱发的发生率高于FOLFOX4方案组,差异有统计学意义(P < 0.05)?结论:DOF方案治疗进展期胃癌疗效较好,不良反应可耐受,值得临床上推广应用?

Efficacy evaluation of the combination chemotherapy of docetaxel,oxaliplatin and fluorouracil on advanced gastric cancer

Objective: To evaluate the efficacy and toxicity of the combination chemotherapy of docetaxel, oxaliplatin and fluorouracil (DOF regimen) on advanced gastric cancer. Methods: Sixty-five patients with advanced gastric cancer were randomized into DOF regimen group(n = 33) and FOLFOX4 regimen group (n = 32). Clinical efficacy and adverse reactions were observed in the two groups. Results: The objective response rate was 51.5% in DOF regimen group. The median TTP in DOF regimen group was 8.6 months and the one year survival rate was 57.3%. In FOLFOX4 regimen group, the objective response rate was 46.9%%. The median TTP was 5.8 months and the one year survival rate was 41.2%. Statistical analysis indicated that the two groups had similar objective response rate (P > 0.05); TTP and one year survival rate in DOF regimen group were better than FOLFOX4 regimen group(P <0.05); The incidences of neutropenia, thrombocytopenia and hair loss were higher in DOF regimen group than in the FOLFOX4 regimen group(P < 0.05). Conclusion: DOF regimen is effective in treating advanced gastric cancer and the toxicities can be tolerated. It is worth clinical application and extension.